Advertisement
NTRA vs VCYT
Which Stock Would AI Choose? Natera (NTRA) vs. Veracyte (VCYT) Stock Comparison
Key Takeaways
- Natera (NTRA) holds a significantly larger market capitalization of approximately $29.6 billion compared to Veracyte's (VCYT) $2.64 billion, reflecting greater scale in the precision diagnostics space.
- Both companies reported strong Q4 2025 earnings beats, with NTRA achieving 40% year-over-year revenue growth and guiding for $2.62–$2.7 billion in 2026, outpacing VCYT's 19% growth and 10–13% 2026 outlook.
- VCYT leads year-to-date performance at 21.4%, surpassing NTRA's 9.52%, amid recent market volatility in biotech.
- VCYT is profitable with a trailing P/E ratio of 40.35 and positive EPS of $0.82, while NTRA remains unprofitable at EPS -$1.51.
- Both exhibit high volatility with betas above 1.6, but NTRA's larger test volume and oncology focus (e.g., Signatera MRD test, where MRD stands for minimal residual disease) drive stronger growth catalysts.
Introduction
Natera (NTRA) and Veracyte (VCYT) operate in the precision diagnostics sector, specializing in genomic and cell-free DNA testing for oncology and women's health. This comparison is relevant for growth-oriented investors and traders seeking exposure to biotech innovations amid evolving market sentiment toward high-growth diagnostics firms. Recent earnings momentum and 2026 guidance highlight their relative positioning in a competitive landscape, aiding decisions on momentum plays versus value opportunities in healthcare stocks.
NTRA Overview and Recent Performance
Natera (NTRA), a leader in cell-free DNA testing, focuses on oncology (Signatera), organ health (Prospera), and women's health products. In recent market activity, shares traded around $207, within a 52-week range of $131.81–$256.36. Q4 2025 results showed 40% product revenue growth to strong levels, with gross margins expanding to 66.9%, fueled by record Signatera volume. The company guided 2026 revenue at $2.62–$2.7 billion, signaling sustained expansion. Positive analyst initiations and upcoming Q1 2026 earnings have supported sentiment, though shares pulled back from peaks amid broader biotech rotation, with YTD gains at 9.52%.
VCYT Overview and Recent Performance
Veracyte (VCYT) develops genomic diagnostics for cancer, including Afirma and Decipher tests. Shares recently hovered near $33, in a 52-week range of $22.61–$50.71. Q4 2025 delivered 19% total revenue growth to $517 million and testing revenue up 21%, with profitability improving. Management reaffirmed 10–13% 2026 revenue growth amid product launches like MRD tests. Recent stability above the 50-day moving average and YTD performance of 21.4% reflect resilient demand, though shares remain below highs amid sector pressures and anticipation for Q1 2026 results.
Trending AI Robots
Tickeron's Trending AI Robots page showcases 25 top-performing AI trading bots curated from over 350 available bots that trade thousands of tickers across diverse strategies, timeframes, and styles—from short-term scalping (15 minutes) to swing trades (up to 49 days). These bots display impressive stats, including annualized returns from +23% to +163%, win rates of 51–88%, profit factors up to 11.7, and profit-to-drawdown ratios exceeding 17 in leading examples. Top performers target sectors like semiconductors, industrials, and energy, with neither NTRA nor VCYT featured. Explore these bots to align automated strategies with current market conditions and enhance your trading edge.
Head-to-Head Comparison
Both firms leverage genomic insights for oncology, but NTRA's cell-free DNA platform emphasizes liquid biopsies and MRD monitoring, contrasting VCYT's tissue-based genomic profiling. Growth drivers favor NTRA with higher revenue acceleration (40% vs. 19% recent) and test volumes over 3.3 million annually, versus VCYT's steady testing expansion. Recent momentum shows VCYT outperforming YTD, but NTRA exhibits stronger analyst conviction via outperform ratings. Risks include high betas (1.68 for NTRA, 1.88 for VCYT) and reimbursement dependencies in diagnostics. Sector exposure ties them to biotech sentiment, where NTRA's scale offers stability trade-offs against VCYT's profitability edge.
Tickeron AI Verdict
Tickeron's AI currently leans toward NTRA due to superior trend consistency in revenue growth, expansive 2026 guidance, and oncology catalysts like Signatera adoption, positioning it favorably for momentum in precision medicine. While VCYT provides profitability and recent relative strength, NTRA's scale and volume suggest higher probabilistic upside in the near term, barring earnings surprises.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NTRA is a Hold and VCYT is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
NTRA’s FA Score shows that 0 FA rating(s) are green whileVCYT’s FA Score has 0 green FA rating(s).
- NTRA’s FA Score: 0 green, 5 red.
- VCYT’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
NTRA’s TA Score shows that 3 TA indicator(s) are bullish while VCYT’s TA Score has 5 bullish TA indicator(s).
- NTRA’s TA Score: 3 bullish, 6 bearish.
- VCYT’s TA Score: 5 bullish, 5 bearish.
Price Growth
NTRA (@Medical Specialties) experienced а -5.87% price change this week, while VCYT (@Medical Specialties) price change was +18.68% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was +0.85%. For the same industry, the average monthly price growth was +2.49%, and the average quarterly price growth was -7.30%.
Reported Earning Dates
NTRA is expected to report earnings on Jul 30, 2026.
VCYT is expected to report earnings on Aug 11, 2026.
Industries' Descriptions
@Medical Specialties (+0.85% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| NTRA | VCYT | NTRA / VCYT | |
| Capitalization | 28.5B | 3.17B | 900% |
| EBITDA | -227.7M | 112M | -203% |
| Gain YTD | -13.073 | -5.701 | 229% |
| P/E Ratio | N/A | 36.76 | - |
| Revenue | 2.5B | 542M | 461% |
| Total Cash | 1.09B | 439M | 248% |
| Total Debt | 240M | 39.3M | 611% |
NTRA | VCYT | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 14 | 9 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 59 Fair valued | 65 Fair valued | |
PROFIT vs RISK RATING 1..100 | 49 | 100 | |
SMR RATING 1..100 | 94 | 79 | |
PRICE GROWTH RATING 1..100 | 60 | 43 | |
P/E GROWTH RATING 1..100 | 100 | 93 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NTRA's Valuation (59) in the Biotechnology industry is in the same range as VCYT (65). This means that NTRA’s stock grew similarly to VCYT’s over the last 12 months.
NTRA's Profit vs Risk Rating (49) in the Biotechnology industry is somewhat better than the same rating for VCYT (100). This means that NTRA’s stock grew somewhat faster than VCYT’s over the last 12 months.
VCYT's SMR Rating (79) in the Biotechnology industry is in the same range as NTRA (94). This means that VCYT’s stock grew similarly to NTRA’s over the last 12 months.
VCYT's Price Growth Rating (43) in the Biotechnology industry is in the same range as NTRA (60). This means that VCYT’s stock grew similarly to NTRA’s over the last 12 months.
VCYT's P/E Growth Rating (93) in the Biotechnology industry is in the same range as NTRA (100). This means that VCYT’s stock grew similarly to NTRA’s over the last 12 months.
| NTRA | VCYT | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 90% |
| Stochastic ODDS (%) | 2 days ago 74% | 2 days ago 88% |
| Momentum ODDS (%) | 2 days ago 83% | 2 days ago 83% |
| MACD ODDS (%) | 2 days ago 83% | N/A |
| TrendWeek ODDS (%) | 2 days ago 77% | 2 days ago 76% |
| TrendMonth ODDS (%) | 2 days ago 80% | 2 days ago 80% |
| Advances ODDS (%) | 6 days ago 80% | 9 days ago 73% |
| Declines ODDS (%) | 14 days ago 78% | 2 days ago 80% |
| BollingerBands ODDS (%) | 2 days ago 77% | 2 days ago 77% |
| Aroon ODDS (%) | 2 days ago 84% | 2 days ago 81% |
Advertisement